Cariprazine + Placebo
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Depression
Conditions
Depression, Bipolar I Disorder
Trial Timeline
Apr 28, 2021 → Mar 1, 2027
NCT ID
NCT04777357About Cariprazine + Placebo
Cariprazine + Placebo is a phase 3 stage product being developed by AbbVie for Depression. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04777357. Target conditions include Depression, Bipolar I Disorder.
What happened to similar drugs?
13 of 20 similar drugs in Depression were approved
Approved (13) Terminated (2) Active (6)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05368558 | Phase 3 | Terminated |
| NCT05384483 | Approved | Completed |
| NCT05439616 | Phase 3 | Completed |
| NCT04777357 | Phase 3 | Recruiting |
| NCT03738215 | Phase 3 | Completed |
| NCT03593213 | Phase 3 | Terminated |
| NCT03573297 | Phase 3 | Completed |
Competing Products
20 competing products in Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine and Fluoxetine combination (OFC) + Fluoxetine | Eli Lilly | Phase 3 | 40 |
| Duloxetine | Eli Lilly | Approved | 35 |
| FK949E | Astellas Pharma | Phase 3 | 40 |
| Quetiapine | Astellas Pharma | Pre-clinical | 26 |
| duloxetine + escitalopram + placebo | Eli Lilly | Phase 3 | 40 |
| duloxetine | Eli Lilly | Approved | 43 |
| Duloxetine Hydrochloride | Eli Lilly | Phase 3 | 40 |
| Duloxetine | Eli Lilly | Approved | 43 |
| Duloxetine | Eli Lilly | Approved | 43 |
| Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro) | Eli Lilly | Approved | 43 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine | Eli Lilly | Approved | 43 |
| duloxetine + fluoxetine + citalopram + paroxetine + sertraline | Eli Lilly | Approved | 43 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 40 |
| Olanzapine + Fluoxetine + Placebo | Eli Lilly | Phase 3 | 32 |
| duloxetine + duloxetine | Eli Lilly | Pre-clinical | 26 |
| olanzapine + ziprasidone | Eli Lilly | Approved | 43 |
| Olanzapine Fluoxetine Combination (OFC) + Placebo | Eli Lilly | Approved | 43 |
| Drug treatment with Cymbalta | Eli Lilly | Approved | 39 |
| Duloxetine | Eli Lilly | Approved | 43 |